

No. 556966-4955  
January 22, 2026



## **Elicera Therapeutics' CSO invited to present at multiple scientific conferences**

Gothenburg, January 22, 2024 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on CAR T-cell therapies and oncolytic viruses, armed with its proprietary and commercially available technology platform iTANK, announces that the company's Chief Scientific Officer, professor Magnus Essand, has been invited to hold presentations on CAR T-cells and the iTANK-platform at multiple scientific conferences

### ***EBMT-EHA 8th European CAR T-cell Meeting, 12-14 February 2026***

Palma de Mallorca, Spain

Title of presentation: *NAP CAR T cells for solid tumors*

<https://www.ebmt.org/events/ebmt-eha-8th-european-car-t-cell-meeting>

### ***10th Zurich Immuno-Oncology Conference 2026, 6 March 2026***

Zürich, Switzerland

Title of presentation: *Optimising CAR-T cells for improved efficacy and reduced toxicity*

<https://www.usz.ch/en/event/10th-zurich-immuno-oncology-conference-2026/>

### ***Onkologidagarna, 17-19 March 2026***

Göteborg, Sweden

Paneldiskussion: *Framtidens terapier*

<https://onkologidagarna.se>

### ***Karolinska Cancersymposium, Frontiers in Cancer Research and Therapy, 19-20 March 2026***

Stockholm, Sweden

Title of presentation: *Optimising CAR-T cells for improved efficacy and reduced toxicity*

<https://news.ki.se/calendar/conference-frontiers-in-cancer-research-and-therapy-2026>

### ***The 4rd Copenhagen symposium on Advances in T cell therapy and Cellular engineering (CATC) 2026, 28-29 May 2026***

Kongens Lyngby, Denmark

<https://catc.dtu.dk>

**For further information, please contact:**

Jamal El-Mosleh, CEO, Elicera Therapeutics AB (publ)

Phone: +46 (0) 703 31 90 51

[jamal.elmosleh@elicera.com](mailto:jamal.elmosleh@elicera.com)

**Certified Advisor**

DNB Carnegie Investment Bank (publ)

**About Elicera Therapeutics AB**

Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company's CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK-platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through exclusive out-licensing agreements. The company's share is traded on Nasdaq First North Growth Market. For additional information, visit [www.elicera.com](http://www.elicera.com).